“NK Cell Therapy Pipeline” report has been added to DelveInsight
NK Cell Therapy: Overview
Natural Killer (NK) Cells are recognized for their ability to kill cancerous cells. These are lymphocytes hailing from the same family as that of T and B cells, however, NK cells are classified as group I Innate Lymphocytes (ILCs) and respond quickly to a wide variety of conditions including cancer.
NK Cell Therapy: Function
Natural killer (NK) cells are granular lymphocytes that play important roles in immunity against viruses and in the immune surveillance of tumors. In addition to being a potent innate source of IFN-γ, NK cells hold cytoplasmic granula that contain perforin and granzymes involved in cell-mediated cytotoxicity.
NK Cell Therapy Pipeline
DelveInsight’s, “NK Cell Therapy – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
NK Cell Therapy Pipeline: Key Players
NK Cell Therapy Pipeline: Report
NK Cell Therapy: NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK Cell Therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells.
NK Cell Therapy Pipeline: Emerging Drugs Chapters
This segment of the NK Cell Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NK Cell Therapy Emerging Drugs
haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest
NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio’s IL-15 superagonist for the treatment of advanced refractory metastatic Merkel cell carcinoma. The therapy leverages the company’s hANK Cell Platform. The drug is in Phase II of clinical development.
Request free sample copy- https://www.delveinsight.com/sample-request/nk-cell-therapy-pipeline-insight
Table of Content
NK Cell Therapy Pipeline: Report Insights
NK Cell Therapy Pipeline: Report Assessment
What are the NK Cell Therapy Report Highlights?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/